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a b s t r a c t
Objectives: The aim of the study was to evaluate the clinical outcome and toxicity after
adjuvant whole abdominal radiotherapy (WART) in patients with ovarian cancer.
Material and methods: Ten patients with optimal cytoreduced ovarian cancer, with a mean
age of 58 years (40–70) and stage Ic: 4, stage II: 2, stage III: 4, were treated with WART and
adjuvant chemotherapy (9/10). The total radiation dose was 22.5Gy in the whole abdomen
and 42–45Gy in the pelvis.
Results: The mean follow-up was 8 years. The 5-year actuarial disease-free survival (DFS)
was 60%, and the overall survival (OS) was 70%. Four patients had disease recurrence. The
sites of recurrence were the abdomen in 2 patients and distant metastases in the other
2 patients (liver and brain metastasis). Gastrointestinal toxicity was as follows: acute 3/10eywords:
varian cancer
hole abdominal radiotherapy
grades I and II, and late toxicity: 2/10 grades I and II, and only 1 patient developed small
bowel obstruction (SBO) that required surgery.
Conclusions:Whole abdominal radiotherapyafter surgery andplatinum-based chemotherapy
achieves high locoregional disease control with an acceptable risk of acute toxicity.
ie On
astrointestinal toxicity
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. Introduction
pithelial ovarian cancer represents the ﬁrst cause of death
rom gynaecological cancer in Western countries, with
pproximately 26,000 new cases diagnosed in the United
tates each year.1–3
More than two-thirds of patients with epithelial ovarian
ancer are diagnosed in an advanced stage of disease at pre-
entation because of the absence of speciﬁc symptoms and
igns. Tumour stage is the most important prognostic factor.
ccording to the annual report of the International Federa-
ion of Gynecology and Obstetrics (FIGO),4 the 5-year overall
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survival ranges from 89% for stage IA to 13% for stage IV dis-
ease.
Chemotherapy-based platinum and paclitaxel is currently
considered the standard of treatment after surgical staging
and resection of abdominal and pelvic disease. A high pro-
portion of patients (60–80%) with advanced ovarian epithelial
cancer respond to ﬁrst-line chemotherapy, but most of these
patients (about 70%) will later have disease progression and
thus be candidates for second-line chemotherapy. The selec-
tion of salvage therapy is commonly based onwhetherwomen
are sensitive or resistant to initial treatment.5
Unfortunately, despite the advances in surgical cytoreduc-
tion and chemotherapy, many patients develop abdominal
d. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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or pelvic recurrence, with a low response rate to further
chemotherapy and with subsequent poor prognosis. Abdom-
inal radiotherapy offers the possibility of improved tumour
control in patients classiﬁed by Dembo as intermediate risk
with microscopic residuum after optimal surgical cytore-
duction and chemotherapy.6 Consequently, the potential
role of radiotherapy for improving disease control in the
abdomen and pelvis may increase the disease-free interval
and survival.7
The aims of the present study were to analyse the clinical
outcome and survival time and to evaluate the acute toxicity
of whole abdominal radiotherapy (WART).
2. Materials and methods
From March 1993 to January 1998, 10 patients diag-
nosed with ovarian cancer were treated with WART. All
patients underwent initial surgical staging and cytoreduc-
tion. This included total abdominal hysterectomy, bilateral
salpingo-oophorectomy, cytological examination of ascites or
peritoneal washings, thorough inspection of the abdomen
and pelvis, infracolic omentectomy, and targeted biopsies of
suspected metastases. CA-125 was determined preoperatively
and postoperatively. Chest X-ray and computed tomography
(CT) scan of the abdomen and pelvis were obtained postoper-
atively as a baseline for future comparison.
There were 4 FIGO stage Ic, 2 Stage IIc and 4 Stage IIIc
tumours. The most frequent histological diagnosis (n=8) was
serous papillary adenocarcinoma followed by 1 case of clear
cell carcinoma and 1 case of poorly differentiated ovarian car-
cinoma. The residual macroscopic tumour remaining after
surgery was ≤2 cm. Thus, according to the risk classiﬁcation
of Dembo et al.,8,9 all patients were classiﬁed as intermediate
risk and assigned to receive additional adjuvant treatment.
Table 1 describes the risk groups of the Dembo criteria.
Nine patients received 6 cycles of platinum-based
chemotherapy before WART. The chemotherapy consisted of
6 cycles of carboplatin (300mg/m2) plus cyclophosphamide
(500mg/m2) in 5 patients, 6 cycles of cisplatin (80mg/m2) plus
cyclophosphamide (500mg/m2) in 3 patients and Adriamycin
(50mg/m2) plus TDCI plus cisplatin (80mg/m2) in 1 patient.
One patient did not receive further adjuvant chemother-
apy due to medical contraindications for chemotherapy and
remained free of disease until the onset of the second malig-
nancy, a clear cell carcinoma of the kidney.
The radiotherapy technique was parallel opposed ante-
rior and posterior whole abdominal ﬁelds, 6–18MV photons.
The superior margin of the ﬁeld was 1.5–2 cm above the
diaphragm and the inferior margin extended below the obtu-
rator foramina. The total dose delivered was 22.5Gy to the
Table 1 – The Dembo criteria8.diotherapy 1 5 ( 2 0 1 0 ) 27–30
whole abdomen at mid-plane with an additional boost to the
pelvis up to a total dose of 42–45Gy, in daily fractions of 1.25Gy,
5 days/week. All patients were treated without shielding the
liver. The kidneys were shielded from the posterior beam by 5
half-value layers of lead placed on a satellite platform. These
kidney shields were introduced at 15Gy to maintain the total
kidney dose below 20Gy. Kidney localization was performed
by X-ray examination of the renal pelvis using endovenous
radiopaque contrast or by demarcation of the renal silhou-
ette on abdominal radiography. Gastrointestinal toxicity was
graded according to the EORTC/RTOG score toxicity.10
Disease progression was deﬁned as: new lesions, consis-
tent with new sites of disease, on imaging—including CT,
magnetic resonance imaging (MRI), ultrasound, scintigraphy
and/or plain X-ray; new elevation of CA-125; biopsy/histology
of new lesions and new signs on clinical exam or symptoms
consistent with new sites of disease. Disease-free survival
(DFS) was calculated from the date of diagnosis to the date of
recurrence of ovarian cancer at any site of the body. Actuarial
survival curves were calculated by the Kaplan–Meier method.
3. Results
The mean age at diagnosis was 58 years old (range: 40–70). The
mean follow-up was 8 years (range: 2–14). The mean survival
time (MST) for the entire group was 104 months (95% conﬁ-
dence interval (CI): 71–136 months). Seven out of 10 patients
(70%) died during follow-up, but 3 of them did so for rea-
sons unrelated to ovarian cancer: the ﬁrst died because of
a cerebral haemorrhage, the second as a consequence of an
acute myocardial infarction and the third developed a second
tumour histology of clear cell carcinoma of the kidney.
Four patients (40%) relapsed between 16 and 35 months
after diagnosis. The mean time to disease progression was 117
months (95% CI: 70–163 months). The 5-year actuarial DFS was
60%, and the overall survival (OS) was 70%. The sites of recur-
rencewere the abdomen in 2patients (20%),withnodal relapse
in a poorly differentiated ovarian carcinoma stage IIIc in 1 case
and peritoneal carcinomatosis in a serous papillary carcinoma
stage II in the other patient. Distant metastases were seen in
2 patients (20%) as the ﬁrst site of relapse. The sites involved
were the liver in 1 patient, and the brain in the other. This
unusual isolated location in ovarian cancer was biopsy proven
and previously reported.11 None developed pelvic recurrence.
At the last follow-up, only 3 patients (30%) were alive with-
out evidence of disease. Three of 6 patients without relapse
died because of intercurrent illness (1 cerebral haemorrhage, 1
acute myocardial infarction and 1 developed a second tumour
with histology of clear cell carcinoma of the kidney).
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Table 2 – Pooled series reporting outcomes of small
bowel obstruction (SBO) for intermediate-risk ovarian
cancer after whole abdominal radiation therapy.
Author Total radiation dose (Gy) SBO%
Fyles AJ et al.9 22.5–27.5 3
Dembo AJ8 22.5–25 1.3
Hruby G et al.14 22–25 6.4
Lindner H et al.19 22.5 1
Macbeth FR et al.20 22.5 3.5
21reports of practical oncology an
All patients received the treatment without interruption.
he treatment was fairly well tolerated, with 30% (3/10) of the
atients presenting acute gastrointestinal side effects. Neither
rade 3–4 acute complications nor mortality while receiving
reatment were observed. Only 2 patients (20%) developed late
ide effects grade 1–2, andonly 1 patient (10%) developed small
owel obstruction (SBO) that required surgery 24 months after
ART, although surgery was performed 4 times before treat-
ent with irradiation (the ﬁrst surgery was an appendectomy,
0 years before the diagnosis of ovarian cancer; the second
ntervention was an exploratory laparotomy to determine the
iagnosis; the third consisted of total abdominal hysterec-
omy, bilateral salpingo-oophorectomy, cytology of ascites or
eritoneal washing, thorough inspection of the abdomen and
elvis, and infracolic omentectomy as crunched oncology; and
he last surgery was a second look after the chemotherapy
reatment).
. Discussion
hemotherapy is the main standard adjuvant treatment for
varian carcinoma. Until the advent of chemotherapy, postop-
rative irradiation was the only adjuvant treatment modality
vailable for advanced ovarian carcinoma. A well-known ran-
omised study by the National Cancer Institute of Canada
eported by Smith and Rutledge12 comparing WART with mel-
halan concluded that both modalities had similar effects in
erms of OS and DFS (the 5-year OS was similar for the 2 arms,
1 and 72% respectively; in FIGO stage I the 5-year DFS was
5 and 90% and the OS 100 and 86% for WART and melphalan
espectively; the differences were not statistically signiﬁcant),
ith less toxicity and eventually lower cost for chemotherapy
eading to a signiﬁcant decline in the use of radiotherapy.
The role of WART was extensively studied by Dembo13
nd the deﬁnition of the intermediate-risk group of patients
ith epithelial ovarian cancer was widely accepted and used
o deﬁne the subgroup of patient candidates for WART. A
ariety of WART techniques and doses have been previously
escribed with comparable results in terms of local control
nd toxicity. Commonly, studies of WART utilize an open
eld technique with abdominal doses of 22.5–30Gy and pelvic
oses of 45–50Gy, with acceptable morbidity and survival.14,3
Recently, the combination of paclitaxel and cis-
latin/carboplatin became the standard treatment for ovarian
ancer. Most of the studies that demonstrated a beneﬁt of this
ombination focused on patients with advanced stage III or
V disease, 20–30% of whom enjoyed long-term disease-free
urvival.15,16 These results have been extrapolated to more
avourable patients.17 However, the high recurrence rates
f more than 60% at 10 years and the presence of residual
isease at second-look laparotomy in approximately half
f the patients, who appeared to be in complete remission
fter chemotherapy, have prompted researchers to con-
ider additional treatments. There is a continued need to
mprove regional control and, therefore, new consolidation
herapies are being developed and tested in the adjuvant
etting. Therapies that have been previously investigated
nclude intraperitoneal 32P, radioimmunotherapy, intraperi-
oneal chemotherapy, and high dose chemotherapy withFirat S et al. 36 11
Schray MF et al.22 30 9
Whelan TJ et al.23 22.5 8.6
Present study 22.5–22 10
haematopoietic support. Most of these therapies have not
undergone sufﬁcient evaluation to conclusively determine
their efﬁcacy. In patients with microscopic residual disease or
complete pathological response in the abdomen and pelvis,
WART consolidation should be considered as an effective
regimen. The stage, grade and amount of residual disease are
widely accepted prognostic factors for ovarian carcinoma for
both chemotherapy and WART. The present study includes
patients at intermediate risk as deﬁned by Dembo.8
The analysis of survival showed 5-year OS rates of 70%,
comparable to previous reports using WART for intermediate-
risk patients (57–80%).18–20 The 5-year DFS rate was 60%,
similar to other results reported with WART or cisplatin-based
chemotherapy that ranged from 45 to 68% at 5 years.11,16
Numerous studies have evaluated the toxicity of WART.
The largest series published was an analysis of 598 patients
reported by Fyles et al.9 showing a 3% incidence of SBO requir-
ing surgery after a total dose of radiation of 22.5–27.5Gy.
Similar rates of SBO have been reported in other studies
with WART of 22.5–30Gy.12,18,19,21 Schray et al.22 reported an
SBO rate of 9% at 3 years with an open ﬁeld technique, and
increased risk was observed with high dose boosting for resid-
ual disease. Another study showed a 9% rate of SBO requiring
surgery for cisplatin chemotherapy followed by WART.23 In
this study, WART>22.5Gy and second-look laparotomy before
WART was associated with an increasing risk of SBO. In our
study, only 1 patient developed SBOwith 3 previous abdominal
operations in addition to surgery for ovarian cancer (Table 2).
To achieve a low rate of small bowel obstructions patients
should be properly selected, without extensive prior abdomi-
nal surgery, avoidance of second-look laparotomy, and use of
a tolerable whole abdominal radiation dose.7,9,22 The results
of our study support the view that the aggressiveness of the
surgeons plays a role in developing future complications after
WART. In previous reports there is no reference concerning
the interval between WART and SBO events, or the relation
with the number of previous abdominal surgeries. SBO events
post-WART are a major concern and SBO may be considered
as secondary to previous surgery itself.
5. ConclusionDeﬁnitive control of abdominal disease in intermediate risk
patients with ovarian cancer still remains a challenge. The
results of the present study show good locoregional control of
disease after chemotherapy and WART, with a low rate of gas-
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trointestinal toxicity, and suggest the need for re-evaluation
of this technique in the management of a well deﬁned subset
of ovarian cancer patients.
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